Caption Management’s BridgeBio Pharma BBIO Stock Holding History

Caption Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-431	Closed	-$30.2K	–	1668
2026 Q1	$32K	Buy	+431	New	+$31.2K	﹤0.01%	1440
2025 Q1	–	Sell	-21,900	Closed	-$738K	–	1519
2024 Q4	$601K	Sell	21,900 -38,100	-64%	-$985K	0.01%	1050
2024 Q3	$1.53M	Sell	60,000 -346,000	-85%	-$9.08M	0.02%	653
2024 Q2	$10.3M	Buy	406,000 +95,566	+31%	+$2.61M	0.16%	136
2024 Q1	$9.6M	Buy	+310,434	New	+$10.6M	0.15%	178
2023 Q4	–	Sell	-90,600	Closed	-$2.72M	–	1340
2023 Q3	$2.39M	Buy	+90,600	New	+$2.57M	0.04%	532
2023 Q2	–	Sell	-46,817	Closed	-$704K	–	1103
2023 Q1	$776K	Buy	+46,817	New	+$546K	0.02%	684
2022 Q2	–	Sell	-20,000	Closed	-$167K	–	1453
2022 Q1	$203K	Sell	20,000 -164,651	-89%	-$1.69M	﹤0.01%	1271
2021 Q4	$3.08M	Buy	+184,651	New	+$7.81M	0.03%	631

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Caption Management's BBIO Position: Q2 2026 in Review

Caption Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 431 shares — an estimated $30.2K sold.

Caption Management first reported a position in BBIO in Q4 2021 and held it in 9 quarters. The position peaked at $10.3M in Q2 2024. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Caption Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Caption Management sold 431 BridgeBio Pharma shares in Q2 2026, an estimated $30.2K.
Caption Management first reported a position in BridgeBio Pharma in Q4 2021 and held it in 9 quarters.
Caption Management's BridgeBio Pharma position peaked at $10.3M in Q2 2024.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.